MX2018002633A - Formulaciones de pirofosfato férrico solido soluble, kits y métodos de uso de las mismas. - Google Patents
Formulaciones de pirofosfato férrico solido soluble, kits y métodos de uso de las mismas.Info
- Publication number
- MX2018002633A MX2018002633A MX2018002633A MX2018002633A MX2018002633A MX 2018002633 A MX2018002633 A MX 2018002633A MX 2018002633 A MX2018002633 A MX 2018002633A MX 2018002633 A MX2018002633 A MX 2018002633A MX 2018002633 A MX2018002633 A MX 2018002633A
- Authority
- MX
- Mexico
- Prior art keywords
- ferric pyrophosphate
- soluble ferric
- kits
- methods
- same
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 6
- 239000007787 solid Substances 0.000 title abstract 5
- SXAWSYZURCZSDX-UHFFFAOYSA-B hydron;[hydroxy(oxido)phosphoryl] hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+);phosphonato phosphate Chemical compound [H+].[H+].[H+].[H+].[H+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OP([O-])(=O)OP(O)([O-])=O.OP([O-])(=O)OP(O)([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O SXAWSYZURCZSDX-UHFFFAOYSA-B 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000012141 concentrate Substances 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 239000000385 dialysis solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
- A61M1/1656—Apparatus for preparing dialysates
- A61M1/1666—Apparatus for preparing dialysates by dissolving solids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562214908P | 2015-09-04 | 2015-09-04 | |
| PCT/US2016/050120 WO2017040937A1 (en) | 2015-09-04 | 2016-09-02 | Solid soluble ferric pyrophosphate formulations, kits, and methods using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018002633A true MX2018002633A (es) | 2019-02-07 |
Family
ID=56926337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018002633A MX2018002633A (es) | 2015-09-04 | 2016-09-02 | Formulaciones de pirofosfato férrico solido soluble, kits y métodos de uso de las mismas. |
Country Status (18)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11278651B2 (en) * | 2018-10-17 | 2022-03-22 | Gambro Lundia Ab | Membrane and device for treating restless leg syndrome |
| CN110063965A (zh) * | 2019-06-04 | 2019-07-30 | 吉林省富生医疗器械有限公司 | 一种血液透析浓缩物 |
| FR3109734B1 (fr) * | 2020-05-04 | 2025-04-11 | Univ Claude Bernard Lyon | Système de dialyse pour le traitement du sepsis |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5177068A (en) * | 1984-04-19 | 1993-01-05 | National Research Development Corporation | Pharmaceutical compositions |
| WO1997014407A1 (en) * | 1995-10-17 | 1997-04-24 | Research Triangle Pharmaceuticals | Insoluble drug delivery |
| US6779468B1 (en) | 1997-08-07 | 2004-08-24 | Ajay Gupta | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
| US6689275B1 (en) | 1996-12-31 | 2004-02-10 | Ajay Gupta | Method and pharmaceutical composition for replacing iron losses in dialysis patients |
| JP3778240B2 (ja) | 1998-06-22 | 2006-05-24 | ライオン株式会社 | 不快な味がマスキングされた造粒組成物及びその製造方法 |
| CA2344548C (en) * | 1998-09-18 | 2007-03-13 | Rockwell Medical Technologies, Inc. | Method and apparatus for preparing liquid dialysate |
| WO2001080828A2 (en) * | 2000-04-20 | 2001-11-01 | Rtp Pharma Inc. | Improved water-insoluble drug particle process |
| CA2433169A1 (en) | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Porous substances and methods for producing the same |
| JP2002302435A (ja) * | 2000-12-26 | 2002-10-18 | Takeda Chem Ind Ltd | 多孔性物質およびその製造法 |
| US7754243B2 (en) * | 2004-08-03 | 2010-07-13 | Clemson University Research Foundation | Aqueous suspension of nanoscale drug particles from supercritical fluid processing |
| US20060134227A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Compositions including iron |
| US7857977B2 (en) * | 2005-07-12 | 2010-12-28 | Rockwell Medical Technologies, Inc. | Packaging of ferric pyrophosphate for dialysis |
| EP1743530B1 (en) * | 2005-07-15 | 2011-08-31 | Unilever N.V. | Iron fortified food product and additive |
| US7816404B2 (en) * | 2007-07-20 | 2010-10-19 | Rockwell Medical Technologies, Inc. | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions |
| US8178709B2 (en) | 2009-07-21 | 2012-05-15 | Biolink Life Sciences, Inc. | Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof |
| WO2012092305A2 (en) | 2010-12-27 | 2012-07-05 | Incube Labs, Llc | Nanonized iron compositions and methods of use thereof |
| WO2014121155A1 (en) | 2013-02-01 | 2014-08-07 | Charak Llc | Methods of treating iron deficiency with soluble ferric pyrophosphate |
-
2016
- 2016-09-02 BR BR112018004244A patent/BR112018004244A2/pt not_active IP Right Cessation
- 2016-09-02 US US15/756,286 patent/US11517555B2/en active Active
- 2016-09-02 PE PE2018000341A patent/PE20181162A1/es not_active Application Discontinuation
- 2016-09-02 MX MX2018002633A patent/MX2018002633A/es unknown
- 2016-09-02 UA UAA201803454A patent/UA124923C2/uk unknown
- 2016-09-02 EA EA201890642A patent/EA201890642A1/ru unknown
- 2016-09-02 WO PCT/US2016/050120 patent/WO2017040937A1/en not_active Ceased
- 2016-09-02 JP JP2018511682A patent/JP7055738B2/ja not_active Expired - Fee Related
- 2016-09-02 AU AU2016315877A patent/AU2016315877B2/en not_active Expired - Fee Related
- 2016-09-02 CN CN201680064674.5A patent/CN108601738A/zh active Pending
- 2016-09-02 SG SG10202107245UA patent/SG10202107245UA/en unknown
- 2016-09-02 EP EP16766192.5A patent/EP3344235A1/en not_active Withdrawn
- 2016-09-02 CA CA2997328A patent/CA2997328A1/en not_active Abandoned
- 2016-09-02 KR KR1020187009195A patent/KR20180050346A/ko not_active Ceased
-
2018
- 2018-02-28 IL IL257796A patent/IL257796B/en unknown
- 2018-03-02 CL CL2018000566A patent/CL2018000566A1/es unknown
- 2018-03-02 PH PH12018500463A patent/PH12018500463A1/en unknown
- 2018-03-02 CO CONC2018/0002421A patent/CO2018002421A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180050346A (ko) | 2018-05-14 |
| PE20181162A1 (es) | 2018-07-19 |
| JP2018529674A (ja) | 2018-10-11 |
| CA2997328A1 (en) | 2017-03-09 |
| JP7055738B2 (ja) | 2022-04-18 |
| WO2017040937A1 (en) | 2017-03-09 |
| CN108601738A (zh) | 2018-09-28 |
| UA124923C2 (uk) | 2021-12-15 |
| CL2018000566A1 (es) | 2018-08-03 |
| CO2018002421A2 (es) | 2018-07-19 |
| IL257796A (en) | 2018-04-30 |
| AU2016315877B2 (en) | 2022-05-26 |
| EA201890642A1 (ru) | 2018-10-31 |
| SG10202107245UA (en) | 2021-08-30 |
| US20180243256A1 (en) | 2018-08-30 |
| BR112018004244A2 (pt) | 2018-09-25 |
| IL257796B (en) | 2021-09-30 |
| AU2016315877A1 (en) | 2018-04-05 |
| US11517555B2 (en) | 2022-12-06 |
| EP3344235A1 (en) | 2018-07-11 |
| PH12018500463A1 (en) | 2018-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501956A1 (en) | Compositions of obeticholic acid and methods of use | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| MX363347B (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| MD4650B1 (ro) | Derivaţi de chinazolină utilizaţi în tratamentul HIV | |
| MX2020001555A (es) | Preparaciones terapéuticas de glicanos y métodos relacionados con estas. | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| MY187540A (en) | Compounds active towards bromodomains | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| MX2021011906A (es) | Composiciones de liberacion retardada de linaclotida. | |
| MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
| MX2017017124A (es) | 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot). | |
| NZ728847A (en) | Pyrrolidinone derivatives as metap-2 inhibitors | |
| EP3349755A4 (en) | NICOTINE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF | |
| MX2022006304A (es) | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. | |
| MX368268B (es) | Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih). | |
| PH12018500463A1 (en) | Solid soluble ferric pyrophosphate formulations, kits, and methods using the same | |
| WO2014147503A3 (en) | Anti-bag3 antibodies for therapeutic use | |
| MX2016015017A (es) | Composiciones dentifricas con estabilidad mejorada del fluoruro. | |
| PH12018501166B1 (en) | Concentrated gibberellin solution formulations | |
| PL3145490T3 (pl) | Liposomy zawierające kwas dihomo-gamma-linolenowy (dgla), zawierające je preparaty i ich zastosowanie | |
| UA92840U (uk) | Дегідратаційно-дегреасингаційний розчин для пластинації анатомічних препаратів |